New EMEA NSAID Study Could Put Teeth In EU Labeling Suggestion
This article was originally published in The Tan Sheet
Executive Summary
The European Medicines Agency is considering whether it should pursue mandatory NSAID labeling requirements across the European Union that would warn of increased risk of thrombotic events associated with use of products in the category
You may also be interested in...
Naproxen Fares Better Than Ibuprofen In Cardiovascular-Risk Data
Traditional non-selective NSAIDs, with the exception of naproxen, carry similar cardiovascular risk to COX-2 inhibitors, according to results of a study released by the Agency for Healthcare Research & Quality (AHRQ) Sept. 25
EMEA Calls For NSAID Labeling Consistency, Notes “No New Safety Concerns”
Labeling regarding established NSAID safety concerns should be made consistent across European Union member states, the European Medicines Agency said Oct. 17
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.